Categories: NewsPharmaceutical

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Staff

Recent Posts

St. Baldrick’s Foundation Launches June Campaign to Honor Childhood Cancer Survivors and Support Lifesaving Research

Los Angeles, California--(Newsfile Corp. - June 3, 2025) - This National Cancer Survivor Month, St.…

1 hour ago

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell…

1 hour ago

Healthie Launches Dev Assist: AI-Native Tooling for Rapid Healthcare App Development, Powered by the Model Context Protocol (MCP)

New open-source tool connects Healthie's GraphQL API to leading AI assistants via the Model Context…

1 hour ago

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

SOMERVILLE, Mass., June 3, 2025 /PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular…

1 hour ago

Digital Pathology Market worth US$2.75 billion by 2030 with 13.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 3, 2025 /PRNewswire/ -- The global Digital Pathology Market, valued at US$1.29…

1 hour ago

Seven Corners Healthcare Invests in MobileOp4, Advancing Medical Access in Disasters and Rural Communities

CARMEL, Ind., June 3, 2025 /PRNewswire/ -- In further commitment to increasing health care access…

1 hour ago